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Species of Verruconis and species ofOchroconis are dematiaceous fungi generally found in the environment but having the abil-
ity to infect humans, dogs, cats, poultry, and fish. This study presents the antifungal susceptibility patterns of these fungi at the
species level. Forty strains originating from clinical and environmental sources were phylogenetically identified at the species
level by using sequences of the ribosomal DNA internal transcribed spacer (rDNA ITS). In vitro antifungal susceptibility testing
was performed against eight antifungals, using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution
method. The geometric meanMICs for amphotericin B (AMB), flucytosine (5FC), fluconazole (FLC), itraconazole (ITC), vori-
conazole (VRC), and posaconazole (POS) andminimum effective concentrations (MECs) for caspofungin (CAS) and anidulafun-
gin (AFG) across theOchroconis and Verruconis species were as follows, in increasing order. For Verruconis species, the values
(g/ml) were as follows: AFG, 0.04; POS, 0.25; ITC, 0.37; AMB, 0.50; CAS, 0.65; VRC, 0.96; 5FC, 10.45; and FLC, 47.25. ForOchro-
conis species, the values (g/ml) were as follows: AFG, 0.06; POS, 0.11; CAS, 0.67; VRC, 2.76; ITC, 3.94; AMB, 5.68; 5FC, 34.48;
and FLC, 61.33. Antifungal susceptibility ofOchroconis and Verruconiswas linked with phylogenetic distance and thermotoler-
ance. Echinocandins and POS showed the greatest in vitro activity, providing possible treatment options forOchroconis and Ver-
ruconis infections.
Recently, by combinedmolecular phylogeny, morphology, andecology, the taxonomy of the Ochroconis lineage was revised
(1). Two genera were recognized: Ochroconis and Verruconis.
Within melanized filamentous fungi, members ofOchroconis and
Verruconis are morphologically exceptional by having sympodial
conidiogenesis with rhexolytic conidial dehiscence (2). However,
both genera are melanized, oligotrophic, and regularly encoun-
tered in indoor environments, in soil, or in heated habitats, and
some species have the ability to cause superficial, cutaneous, and
systemic infections in immunocompromised patients (3–6).
Verruconis species are thermophilic, with Verruconis gallopava
occurring in hot environments, such as thermal soils, broiler
house litter, hot springs, and self-heated waste (1). Pathology in
Verruconis is restricted to V. gallopava, which is the main agent of
human brain infections and is responsible for encephalitis in
poultry and wild birds (7–15), dogs (16), and cats (17). In con-
trast, Ochroconis species are mesophilic saprobes, with an opti-
mumgrowth temperature between 15 and 30°C and an inability to
grow at 37°C, which occasionally infect cold-blooded vertebrates
(1, 18). Only a single infection was noted in a warm-blooded an-
imal, i.e., a subcutaneous lesion in a cat (19), while the first sub-
cutaneous human infection due to Ochroconis tshawytschae was
recently reported (20).
Despite significant medical and veterinary importance, little is
known regarding the species-specific antifungal susceptibility
profiles of Verruconis and Ochroconis species. The polyene agents
exert their antifungal activity via binding to ergosterol in the fun-
gal cell membrane. This disrupts cell permeability and results in
rapid cell death. Flucytosine exerts antifungal activity via inhibi-
tion of both DNA synthesis and protein synthesis in the fungal
cell. Azole agents exert their antifungal activity by blocking the
demethylation of lanosterol, thereby inhibiting ergosterol synthe-
sis. The mechanism of activity of the echinocandins is inhibition
of the production of (1,3)--D-glucan, an essential component in
the fungal cell wall (21). We therefore investigated the in vitro
susceptibilities of a large collection of clinical and environmental
isolates of thermophilic andmesophilic species to eight antifungal
drugs.
(Some of these results were presented at the 53rd Interscience
Conference onAntimicrobial Agents andChemotherapy,Denver,
CO, 10 to 13 September 2013.)
MATERIALS AND METHODS
Fungal strains. Strains used in this study are listed in Table 1, with origin,
identification number, and clinical data for each isolate. In total, 40 strains
from clinical and environmental sources were used. Lyophilized fungal
strains were obtained from the reference collection of the CBS-KNAW
Fungal Biodiversity Centre (CBS, Utrecht, The Netherlands) and selected
according to their historical pathogenicity. In addition, the representative
type species of saprophytic strains were used for environmental isolates of
both genera (Table 1). All isolates were cultured on malt extract agar
(MEA) at 24°C for 14 days.Morphological identifications were confirmed
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by sequence-based analysis of the internal transcribed spacer (ITS) of the
ribosomal DNA (rDNA) region, as described previously (1). Briefly, se-
quences were edited using the SeqMan tool of Lasergene software (DNAS-
tar Inc., Madison, WI) and then aligned interactively using Ward’s aver-
aging in the BioNumerics package v. 4.61 (Applied Maths, Kortrijk,
Belgium). The ITS sequences were finally aligned with the program
MUSCLE (www.ebi.ac.uk/Tools/msa/muscle), and the aligned sequences
were adjusted using BioEdit v. 7.0.5.2. The ITS data set was then analyzed
by use of MEGA5 software (22), in which the Tamura three-parameter
model with gammadistribution (T92G)was searched as the bestmodel.
The maximum likelihood (ML) heuristic method with 1,000-replicate
bootstrapping and the maximum parsimony (MP) method with 1,000-
replicate bootstrapping were performed for tree reconstructions and phy-
logeny tests. To strongly confirm the analyses, the ML method with the
approximate likelihood ratio test (aLRT)was also performedwith PhyML
(23). Trees were viewed and edited with TreeView v. 1.6.6, FigTree v.
1.1.2, and MEGA5.
In vitro antifungal susceptibility testing. In vitro antifungal suscep-
tibility testing was performed using a broth microdilution format against
eight antifungal compounds according to the Clinical and Laboratory
Standards Institute (CLSI) guidelines (24). The final concentrations of the
antifungal agents ranged from 0.016 to 16 g/ml for amphotericin B
(AMB), fluconazole (FLC), itraconazole (ITC), voriconazole (VRC), po-
saconazole (POS), caspofungin (CAS), and anidulafungin (AFG). Flucy-
tosine (5FC) was assayed over a 2-fold concentration range from 0.064 to
64 g/ml. Reading of results was performed using a reading mirror and a
microtitration plate spectrophotometric reader (Anthos htIII; Anthos
Labtec Instruments, Salzburg, Austria).
Ochroconis isolates were incubated at 25°C, and Verruconis isolates
were incubated at 37°C. Agitation of plates was not used. The MICs of
AMB, FLC, 5FC, ITC, VRC, and POS were determined visually with an
invertedmirror by comparison of growth in the wells containing the drug
and that of the drug-free control. The minimum effective concentrations
(MECs) of CAS and AFG were read with a plate microscope (Olympus
SZX9; Olympus Nederland, Zoeterwoude, The Netherlands) at a magni-
fication of25 to50. TheMECwas defined as the lowest concentration
at which abnormal, short, and branched hyphal clusters were observed, in
contrast to the long, unbranched hyphal elements that were seen in the
growth control well.
Paecilomyces variotii (ATCC 22319), Candida parapsilosis (ATCC
22019) and Candida krusei (ATCC 6258) were used as quality controls in
all experiments. The ranges and geometric means (GM) of the MICs and
MECs were determined for each species and drug after 48 to 168 h of
incubation. Furthermore, the MIC50s and MIC90s for the isolates were
calculated by use of the criteria for MIC determinations described above.
The MIC50 and MIC90 values were calculated for those species with 10 or
more isolates. If the MIC values of the replicates were different, the GM
values of the replicates were used for comparison with other isolates. All
experiments were performed in three independent replicates with each
strain on different days.
Statistical analysis.Data analyses were performed by using GraphPad
Prism, version 5.0, for Windows (GraphPad Software, San Diego, CA).
MIC/MEC distributions between isolates were compared by using the
Mann-Whitney-Wilcoxon test. Statistical significance was defined as hav-
ing a P value of0.05 (two-tailed).
RESULTS
All strains were identified to the species level by sequence-based
analysis and tested against eight antifungal compounds. Two gen-
era have been recognized based onmolecular phylogeny, viz.,Ver-
ruconis andOchroconis. In Fig. 1, data are summarized for relevant
species, displaying their mutual phylogenetic distances, interspe-
cies variability according to temperature tolerance, and antifungal
susceptibility profiles per species. GM MICs, MIC ranges, and
MIC50 and MIC90 distributions for eight antifungal agents are
summarized in Table 2.
Overall, visual and spectrophotometric readings gave similar
results for theMIC andMEC endpoints. The GMMICs for AMB,
5FC, FLC, ITC, VRC, and POS and the MEC values for CAS and
AFG across the genera in this study are shown below, in increasing
order. For Verruconis, the values (g/ml) were as follows: AFG,
0.04; POS, 0.25; ITC, 0.37; AMB, 0.50; CAS, 0.65; VRC, 0.96; 5FC,
10.45; and FLC, 47.25. ForOchroconis, the values (g/ml) were as
follows: AFG, 0.06; POS, 0.11; CAS, 0.67; VRC, 2.76; ITC, 3.94;
AMB, 5.68; 5FC, 34.48; and FLC, 61.33. The widest ranges were
seen for FLC (range, 1 to 64 g/ml) and 5FC (range, 0.5 to 64
g/ml). The highest GM MICs were 47.25 g/ml, for FLC, fol-
lowed by 10.45 g/ml, for 5FC. AMBMICs ranged from 0.125 to
16 g/ml, and ITC had a MIC range of 0.016 to 16 g/ml.
POS exhibited potent activity against all strains, with MICs rang-
ing from 0.0016 to 4 g/ml, while the GM MIC of VRC (0.96
g/ml) was 2 log2 dilution steps less potent than that of POS (0.25
g/ml) against thermotolerant strains and 6 log2 dilution steps
less active than in the Ochroconis species (2.76 g/ml VRC versus
0.11g/ml POS). Notably,Ochroconis isolates had higherMICs of
AMB, 5FC, FLC, ITC, and VRC than those for Verruconis strains.
The two echinocandins showed susceptible profiles in theirMECs.
In most cases, AFG had a higher activity than that of CAS (AFG
MEC of 0.04 g/ml versus 0.65 g/ml CAS against Verruconis
strains, and AFG MEC of 0.06 g/ml versus 0.67 g/ml CAS
against Ochroconis species). In addition, various susceptibility
profiles were demonstrated within the genera. ForOchroconis, the
triazole derivatives ITC and VRC and AMB offered significantly
(P 0.05) higher susceptible profiles forO. mirabilis than for the
other species. However, 5FC and FLC were found to be less active
against V. gallopava than against V. calidifluminalis (P 0.05).
DISCUSSION
The genusOchroconis was recently revised and currently contains
13 species (1). Species accepted within the lineage, within the or-
der Venturiales, were keyed out on the basis of molecular phylog-
eny and phenotypic and physiologic characteristics. A new genus,
Verruconis, was proposed for the neurotropic opportunistOchro-
conis gallopava and its close relatives.
Notably, thermotolerance has a significant impact on the vir-
ulence potential of Ochroconis and Verruconis species, as shown
previously in other melanized fungi. Species able to grow at tem-
peratures of 37°C or above (e.g., Cladophialophora bantiana, Exo-
phiala dermatitidis, and Exophiala jeanselmei) (25) may cause sys-
temic or disseminated infections in mammals. The black yeast
Exophiala dermatitidis has a maximum growth temperature of 42
to 45°C and has a natural habitat in association with birds and
bats, which have a body temperature well above that of humans
(26, 27). Mesophilic species with maximum growth temperatures
of 27 to 33°C are restricted to cold-blooded vertebrates (25) or,
occasionally, invertebrates (28, 29).
The availability of in vitro susceptibility profiles according to
the latest taxonomic studies of Ochroconis and Verruconis species
(1) is scant. Our study provides the first antifungal susceptibility
data on a large set of clinical and environmental strains from a
wide range of sources and origins. Our results indicate that ther-
motolerance has a significant impact on the antifungal suscepti-
bility of Ochroconis and Verruconis species. Both thermotolerant
and mesophilic species had susceptibility profiles with a uniform
Antifungal Susceptibility of Ochroconis and Verruconis
June 2014 Volume 58 Number 6 aac.asm.org 3287
 o
n
 M
ay 1, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://aac.asm
.org/
D
ow
nloaded from
 
pattern of lowMICs for POS, AFG, andCAS. VRC, AMB, and ITC
showed efficacy against Verruconis species, with 1-, 3-, and 4-log2
less susceptibility, respectively, than Ochroconis species. The ma-
jority of strains demonstrated high MICs for 5FC and FLC, indi-
cating poor activity of these drugs against the pathogens. Both
echinocandins were found to have potent in vitro activity against
Ochroconis species. This matches previously reported data for
CAS, with a MEC of 0.25 g/ml against Ochroconis tshawytschae
(20) and 0.03 to 1 g/ml against Verruconis gallopava (30, 31).
This is in contrast with previously published data on most
melanized fungi, which appear to be tolerant to echinocandins,
probably due to the presence of melanin, which prevents penetra-
tion of antifungals into fungal cells (32). Nevertheless,O.mirabilis
demonstrated less susceptibility to ITC, VRC, and AMB (P 
0.05) than the otherOchroconis species, andV. calidifluminaliswas
more susceptible to 5FC and FLC than V. gallopava (P 0.05).
Given that the echinocandins and the triazole POS showed the
highest in vitro activity against thermotolerant and mesophilic
species, a possible treatment option forOchroconis andVerruconis
infections in both warm-blooded (human) and cold-blooded an-
imals may be provided. The triazole POS is an expanded-spec-
trum triazole with fungicidal activity against a wide spectrum of
molds, including Aspergillus species and members of the Muco-
rales, as well as enhanced activity againstCandida and other yeasts
(33). The echinocandins represent the newest class of antifungals
that exhibit fungicidal activity against many Candida species,
making this drug class a desirable alternative to the azole agents,
which exhibit only static activity against yeasts. Because mamma-
lian cells have no cell wall, the echinocandins have very few ad-
verse effects in humans (33).
In general, the divergent antifungal profiles of the Verruconis
and Ochroconis genera and the interspecies variability observed
FIG 1 MEGA5 maximum likelihood tree created from ITS sequences ofOchroconis and Verruconis isolates. The geometric mean susceptibility profiles of eight
antifungals against each species have been incorporated into the figure. Numbers on branches are percent bootstrap values obtained from ML, aLRT, and MP
analyses. Type strains are highlighted by a “T.” ND, not determined.
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TABLE 2 Geometric mean MICs, MIC ranges, MIC50s, and MIC90s
obtained by susceptibility testing of antimycotic agents against
Ochroconis and Verruconis spp.
Organism (n) and drug
MIC or MEC (mg/liter)a
Range 50% 90%
Geometric
mean
All thermotolerant strains
(Verruconis spp.)
(n 20)
Amphotericin B 0.125–4 0.25 0.5 0.50
Flucytosine 0.5–64 4 32 10.45
Fluconazole 1–64 64 64 47.25
Itraconazole 0.016–4 0.125 0.5 0.37
Voriconazole 0.063–2 1 2 0.96
Posaconazole 0.016–4 0.031 0.125 0.25
Caspofungin 0.25–1 0.5 1 0.65
Anidulafungin 0.016–0.125 0.031 0.063 0.04
All mesophilic strains
(Ochroconis spp.)
(n 20)
Amphotericin B 0.25-16 2 16 5.68
Flucytosine 0.125-64 16 64 34.48
Fluconazole 8-64 64 64 61.33
Itraconazole 0.016–16 0.25 16 3.94
Voriconazole 0.125–8 2 8 2.76
Posaconazole 0.016–0.25 0.063 0.25 0.11
Caspofungin 0.063–2 0.5 1 0.67
Anidulafungin 0.016–0.25 0.031 0.125 0.06
V. gallopava (n 18)
Amphotericin B 0.125–4 0.25 0.5 0.54
Flucytosine 0.5–64 4 32 11.53
Fluconazole 4-64 64 64 52.22
Itraconazole 0.016–4 0.125 0.5 0.40
Voriconazole 0.5–2 1 2 1.06
Posaconazole 0.016–4 0.031 0.125 0.28
Caspofungin 0.25–1 0.5 1 0.64
Anidulafungin 0.016–0.125 0.031 0.063 0.04
V. calidifluminalis (n 2)
Amphotericin B 0.063–0.125 NC NC 0.094
Flucytosine 0.5–1 NC NC 0.75
Fluconazole 1–4 NC NC 2.5
Itraconazole 0.16 NC NC 0.016
Voriconazole 0.063–0.125 NC NC 0,.094
Posaconazole 0.16 NC NC 0.016
Caspofungin 0.5–1 NC NC 0.75
Anidulafungin 0.031–0.063 NC NC 0.047
O. mirabilis (n 8)
Amphotericin B 1-16 NC NC 12.625
Flucytosine 8–64 NC NC 21
Fluconazole 64 NC NC 64
Itraconazole 0.25–64 NC NC 10.09375
Voriconazole 2–8 NC NC 5.75
Posaconazole 0.063–0.25 NC NC 0.211
Caspofungin 0.5–1 NC NC 0.75
Anidulafungin 0.031–0.125 NC NC 0.05475
O. tshawytschae (n 2)
Amphotericin B 0.125–64 NC NC 2
Flucytosine 8–64 NC NC 32.0625
TABLE 2 (Continued)
Organism (n) and drug
MIC or MEC (mg/liter)a
Range 50% 90%
Geometric
mean
Fluconazole 0.016–0.25 NC NC 36
Itraconazole 0.125–0.5 NC NC 0.133
Voriconazole 0.016–0.125 NC NC 0.3125
Posaconazole 1–2 NC NC 0.125
Caspofungin 0.125–0.25 NC NC 1.5
Anidulafungin 0.031–0.125 NC NC 0.1875
O. constricta (n 3)
Amphotericin B 1–2 NC NC 1.33
Flucytosine 64 NC NC 64.00
Fluconazole 64– 64 NC NC 64.00
Itraconazole 0.063 NC NC 0.06
Voriconazole 0.5–1 NC NC 0.67
Posaconazole 0.016 NC NC 0.02
Caspofungin 0.063–0.5 NC NC 0.35
Anidulafungin 0.031 NC NC 0.03
Ochroconis sp. (n 1)
Amphotericin B 4 NC NC NC
Flucytosine 64 NC NC NC
Fluconazole 64 NC NC NC
Itraconazole 0.25 NC NC NC
Voriconazole 0.25 NC NC NC
Posaconazole 0.031 NC NC NC
Caspofungin 0.5 NC NC NC
Anidulafungin 0.016 NC NC NC
O. cordanae (n 1)
Amphotericin B 1 NC NC NC
Flucytosine 16 NC NC NC
Fluconazole 64 NC NC NC
Itraconazole 0.25 NC NC NC
Voriconazole 2 NC NC NC
Posaconazole 0.016 NC NC NC
Caspofungin 0.5 NC NC NC
Anidulafungin 0.031 NC NC NC
O. humicola (n 1)
Amphotericin B 1 NC NC NC
Flucytosine 64 NC NC NC
Fluconazole 64 NC NC NC
Itraconazole 0.125 NC NC NC
Voriconazole 1 NC NC NC
Posaconazole 0.063 NC NC NC
Caspofungin 1 NC NC NC
Anidulafungin 0.125 NC NC NC
O. minima (n 1)
Amphotericin B 1 NC NC NC
Flucytosine 8 NC NC NC
Fluconazole 64 NC NC NC
Itraconazole 0.063 NC NC NC
Voriconazole 0.5 NC NC NC
Posaconazole 0.016 NC NC NC
Caspofungin 0.5 NC NC NC
Anidulafungin 0.031 NC NC NC
O. gamsii (n 1)
Amphotericin B 1 NC NC NC
(Continued on following page)
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forO. mirabilis and V. calidifluminalis clearly suggest that routine
in vitro susceptibility testing can be useful for obtaining reliable
information on treatment options. Until now, there have been no
guidelines for optimal antifungal regimens for Ochroconis and
Verruconis species. Although various efficacies have been docu-
mented (34), several studies suggest that POS and ITC may pro-
vide optimal therapies forOchroconis infection, followed by AMB
andVRC, and that 5FC and FLC are the least effective drugs (6, 30,
31, 35, 36), which is in agreement with the in vitro results of the
present study.
Treatment of Verruconis infections with VRC is supported by
in vitro results, and it proved to be active in a chronic granuloma-
tous disease (CGD) patient (34). VRC has an optimal oral bio-
availability and penetration to the blood-brain barrier, indicating
its use for cerebral infections. In some cases of V. gallopava infec-
tions, AMB was also used successfully in empirical antifungal
therapy (37). However, further studies are required to establish
the optimal treatment. In addition, as recommended for other
fungal infections, supportive management strategies, such as sur-
gical excision of lesions, are recommendedwhenever feasible (34).
Early diagnosis and treatment are also mandatory in order to
avoid dissemination to the brain, which carries a very poor prog-
nosis (20).
In conclusion, although there are no clinically defined break-
points forVerruconis andOchroconis species and the lack of inter-
pretative breakpoints makes MICs difficult to interpret, antifun-
gal susceptibility testing can be helpful in guiding clinical
management of patients with these infections. Based on the data
presented in the current study, POS and echinocandins were the
antimycotics with the best overall activity, having broad-spectrum
activity against both thermotolerant and mesophilic species. The
apparently good penetration of POS into the central nervous sys-
tem (CNS), with the MIC falling well below the serum levels
achievable with standard dosing regimens (38), combined with
excellent in vitro data (39) and activity in animal models (40–43),
supports the use of POS for difficult-to-treat disseminated brain
infections. In the clinical setting, POShas beenused successfully in
cases of cerebral and disseminated phaeohyphomycosis (44, 45).
In addition, POS and VRC are routinely recommended for treat-
ment, prophylaxis, and salvage therapy of life-threatening fungal
infections, such as Aspergillus diseases. POS also has a label indi-
cation for the treatment of less common infections, including
chromoblastomycosis, mycetoma, and coccidioidomycosis.
Therefore, standard dosing regimens and provisional target con-
centrations used for the prevention or treatment of invasive fungal
infections (46) might be optimal tentative suggestions for Verru-
conis and Ochroconis infections.
ACKNOWLEDGMENTS
This publication was prepared as a collaborative study between the CBS-
Fungal BiodiversityCentre,Utrecht, TheNetherlands, theVeterinaryMy-
cology and Black Yeast Working Groups of the International Society for
Human and AnimalMycology (ISHAM), and the Department ofMedical
Microbiology, Radboudumc, Nijmegen, The Netherlands.
S.S., K.S.,W.J.G.M. and G.S.D.H. have no conflicts of interest. J.W.M.
and P.E.V. have served as consultants to and have received research grants
from Astellas, Basilea, Gilead Sciences, Merck, and Pfizer.
REFERENCES
1. Samerpitak K, Van der Linde E, Choi HJ, Gerrits van den Ende AHG,
Machouart M, Gueidan C, de Hoog GS. 2014. Taxonomy of Ochroconis,
genus including opportunistic pathogens on humans and animals. Fungal
Divers. 65:89–126. http://dx.doi.org/10.1007/s13225-013-0253-6.
2. de Hoog GS, Guarro J, Gene J, Figueras MJ. 2009. Atlas of clinical fungi:
the ultimate benchtool for diagnostics. A pilot version of the 3rd ed. Cen-
traalbureau voor Schimmelcultures, KNAW Fungal Biodiversity Centre,
Utrecht, The Netherlands.
3. Silveira F, Nucci M. 2001. Emergence of black moulds in fungal disease:
epidemiology and therapy. Curr. Opin. Infect. Dis. 14:679–684. http://dx
.doi.org/10.1097/00001432-200112000-00003.
4. Qureshi ZA, Kwak EJ, NguyenMH, Silveira FP. 2012. Ochroconis gallopava: a
dematiaceousmold causing infections in transplant recipients. Clin. Transplant.
26:E17–E23. http://dx.doi.org/10.1111/j.1399-0012.2011.01528.x.
5. Cardeau-Desangles I, Fabre A, Cointault O, Guitard J, Esposito L, Iriart X,
Berry A, Valentin A, Cassaing S, Kamar N. 2013. Disseminated Ochroconis
gallopava infection inaheart transplantpatient.Transpl. Infect.Dis.15:E115–
E118. http://dx.doi.org/10.1111/tid.12084.
6. Shoham S, Pic-Aluas L, Taylor J, Cortez K, Rinaldi MG, Shea Y, Walsh
TJ. 2008. Transplant-associated Ochroconis gallopava infections.
Transpl. Infect. Dis. 10:442–448. http://dx.doi.org/10.1111/j.1399-3062
.2008.00327.x.
7. Georg LK, Bierer BW, Cooke WB. 1964. Encephalitis in turkey poults
TABLE 2 (Continued)
Organism (n) and drug
MIC or MEC (mg/liter)a
Range 50% 90%
Geometric
mean
Flucytosine 64 NC NC NC
Fluconazole 64 NC NC NC
Itraconazole 0.25 NC NC NC
Voriconazole 2 NC NC NC
Posaconazole 0.031 NC NC NC
Caspofungin 0.5 NC NC NC
Anidulafungin 0.031 NC NC NC
O. verrucosa (n 1)
Amphotericin B 0.25 NC NC NC
Flucytosine 16 NC NC NC
Fluconazole 64 NC NC NC
Itraconazole 0.25 NC NC NC
Voriconazole 2 NC NC NC
Posaconazole 0.031 NC NC NC
Caspofungin 0.25 NC NC NC
Anidulafungin 0.016 NC NC NC
O. anellii (n 1)
Amphotericin B 1 NC NC NC
Flucytosine 4 NC NC NC
Fluconazole 64 NC NC NC
Itraconazole 0.031 NC NC NC
Voriconazole 0.5 NC NC NC
Posaconazole 0.031 NC NC NC
Caspofungin 0.5 NC NC NC
Anidulafungin 0.031 NC NC NC
O. lascauxensis (n 1)
Amphotericin B 1 NC NC NC
Flucytosine 64 NC NC NC
Fluconazole 64 NC NC NC
Itraconazole 0.25 NC NC NC
Voriconazole 1 NC NC NC
Posaconazole 0.063 NC NC NC
Caspofungin 0.25 NC NC NC
Anidulafungin 0.031 NC NC NC
a The MIC50 and MIC90 values were calculated for those species with 10 or more
isolates. NC, not calculated, because10 strains per species were available for testing.
Seyedmousavi et al.
3290 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 M
ay 1, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://aac.asm
.org/
D
ow
nloaded from
 
due to a new fungus species. Sabouraudia 3:239–244. http://dx.doi.org/10
.1080/00362176485190401.
8. Blalock HG, Georg LK, Derieux WT. 1973. Encephalitis in turkey poults
due to Dactylaria (Diplorhinotrichum) gallopava—a case report and its
experimental reproduction. Avian Dis. 17:197–204. http://dx.doi.org/10
.2307/1588939.
9. Ranck FM, Jr, Georg LK, Wallace DH. 1974. Dactylariosis—a newly
recognized fungus disease of chickens. Avian Dis. 18:4–20. http://dx.doi
.org/10.2307/1589237.
10. Randall CJ, Owen DM, Kirkpatrick KS. 1981. Encephalitis in broiler
chickens caused by a hyphomycete resemblingDactylaria gallopava. Avian
Pathol. 10:31–41. http://dx.doi.org/10.1080/03079458108418456.
11. Shane SM, Markovits J, Snider TG, 3rd, Harrington KS. 1985. Enceph-
alitis attributed to dactylariosis in Japanese quail chicks (Coturnix cotur-
nix japonica). AvianDis. 29:822–828. http://dx.doi.org/10.2307/1590673.
12. KareshWB, Russell R, Gribble D. 1987. Dactylaria gallopava encephalitis
in two grey-winged trumpeters (Psophia crepitans). Avian Dis. 31:685–
688. http://dx.doi.org/10.2307/1590762.
13. Salkin IF, Dixon DM, Kemna ME, Danneman PJ, Griffith JW. 1990.
Fatal encephalitis caused byDactylaria constricta var. gallopava in a snowy
owl chick (Nyctea scandiaca). J. Clin. Microbiol. 28:2845–2847.
14. Connole MD. 1990. Review of animal mycoses in Australia. Mycopatho-
logia 111:133–164. http://dx.doi.org/10.1007/BF02282798.
15. MohapatraN. 1993. Fungal encephalitis in poultry. Poult. Advis. 26:61–62.
16. Singh K, Flood J, Welsh RD, Wyckoff JH, Snider TA, Sutton DA. 2006.
Fatal systemic phaeohyphomycosis caused byOchroconis gallopavum in a
dog (Canis familaris). Vet. Pathol. 43:988–992. http://dx.doi.org/10.1354
/vp.43-6-988.
17. Padhye AA, Amster RL, Browning M, Ewing EP. 1994. Fatal encephalitis
caused byOchroconis gallopava in a domestic cat. J.Med. Vet.Mycol. Res.
32:141–145. http://dx.doi.org/10.1080/02681219480000191.
18. Hatai K, Kubota SS. 1989. A visceral mycosis in cultured masu salmon
(Oncorhynchus masou) caused by a species of Ochroconis. J. Wildl. Dis.
25:83–88. http://dx.doi.org/10.7589/0090-3558-25.1.83.
19. VanSteenhouse JL, Padhye AA, Ajello L. 1988. Subcutaneous phaeohy-
phomycosis caused by Scolecobasidium humicola in a cat. Mycopatholo-
gia 102:123–127. http://dx.doi.org/10.1007/BF00437449.
20. Ge YP, Lv GX, Shen YN, Li M, Deng SW, De Hoog S, Samerpitak K, Liu
WD. 2012. First report of subcutaneous phaeohyphomycosis caused by
Ochroconis tshawytschae in an immunocompetent patient. Med. Mycol.
50:637–640. http://dx.doi.org/10.3109/13693786.2011.653834.
21. Lewis RE. 2011. Current concepts in antifungal pharmacology. Mayo
Clin. Proc. 86:805–817. http://dx.doi.org/10.4065/mcp.2011.0247.
22. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011.
MEGA5: molecular evolutionary genetics analysis using maximum likeli-
hood, evolutionary distance, and maximum parsimony methods. Mol.
Biol. Evol. 28:2731–2739. http://dx.doi.org/10.1093/molbev/msr121.
23. Dereeper A, Guignon V, Blanc G, Audic S, Buffet S, Chevenet F, Dufayard JF,
Guindon S, Lefort V, Lescot M, Claverie JM, Gascuel O. 2008. Phylogeny.fr:
robust phylogenetic analysis for the non-specialist. Nucleic Acids Res. 36:W465–
W469. http://dx.doi.org/10.1093/nar/gkn180.
24. CLSI. 2008. Reference method for broth dilution antifungal susceptibility
testing of filamentous fungi; approved standard, 2nd ed. CLSI document
M38–A2, vol 28, no 16. Clinical and Laboratory Standards Institute,
Wayne, PA.
25. deHoogGS, Vicente VA,NajafzadehMJ,HarrakMJ, Badali H, Seyedmousavi
S. 2011.Waterborne Exophiala species causing disease in cold-blooded animals.
Persoonia 27:46–72. http://dx.doi.org/10.3767/003158511X614258.
26. Sudhadham M, Prakitsin S, Sivichai S, Chaiyarat R, Dorrestein GM,
Menken SB, de Hoog GS. 2008. The neurotropic black yeast Exophiala
dermatitidis has a possible origin in the tropical rain forest. Stud. Mycol.
61:145–155. http://dx.doi.org/10.3114/sim.2008.61.15.
27. Horré R, de Hoog GS. 1999. Primary cerebral infections by melanized
fungi: a review. Stud. Mycol. 43:176–193.
28. Vicente VA, Orelis-Ribeiro R, Najafzadeh MJ, Sun J, Guerra RS, Miesch
S, Ostrensky A, Meis JF, Klaassen CH, de Hoog GS, Boeger WA. 2012.
Black yeast-like fungi associated with lethargic crab disease (LCD) in the
mangrove-land crab, Ucides cordatus (Ocypodidae). Vet. Microbiol. 158:
109–122. http://dx.doi.org/10.1016/j.vetmic.2012.01.031.
29. Seyedmousavi S, Guillot J, de Hoog GS. 2013. Phaeohyphomycoses,
emerging opportunistic diseases in animals. Clin. Microbiol. Rev. 26:19–
35. http://dx.doi.org/10.1128/CMR.00065-12.
30. Mayer N, Bastani B. 2009. A case of pulmonary cavitary lesion due to
Dactylaria constricta var. gallopava in a renal transplant patient. Nephrol-
ogy 14:262. http://dx.doi.org/10.1111/j.1440-1797.2009.01107.x.
31. Wong JS, Schousboe MI, Metcalf SS, Endre ZH, Hegarty JM, Maze MJ,
Keith ER, Seaward LM, Podmore RG. 2010. Ochroconis gallopava peri-
tonitis in a cardiac transplant patient on continuous ambulatory perito-
neal dialysis. Transpl. Infect. Dis. 12:455–458. http://dx.doi.org/10.1111/j
.1399-3062.2010.00523.x.
32. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L.
2004. In vitro activity of anidulafungin against selected clinically impor-
tant mold isolates. Antimicrob. Agents Chemother. 48:1912–1915. http:
//dx.doi.org/10.1128/AAC.48.5.1912-1915.2004.
33. Dodds Ashley ES, Varkey JB, Krishna G, Vickery D, Ma L, Yu X,
Malavade D, Goodwin M, Perfect JR, Power E. 2009. Pharmacokinetics
of posaconazole administered orally or by nasogastric tube in healthy vol-
unteers. Antimicrob. Agents Chemother. 53:2960–2964. http://dx.doi.org
/10.1128/AAC.01178-08.
34. Meriden Z, Marr KA, Lederman HM, Illei PB, Villa K, Riedel S, Carroll KC,
Zhang SX. 2012. Ochroconis gallopava infection in a patient with chronic gran-
ulomatous disease: case report and review of the literature.Med.Mycol. 50:883–
889. http://dx.doi.org/10.3109/13693786.2012.681075.
35. Jenney A, Maslen M, Bergin P, Tang SK, Esmore D, Fuller A. 1998.
Pulmonary infection due to Ochroconis gallopavum treated successfully
after orthotopic heart transplantation. Clin. Infect. Dis. 26:236–237. http:
//dx.doi.org/10.1086/517075.
36. Wang TK, Chiu W, Chim S, Chan TM, Wong SS, Ho PL. 2003.
Disseminated Ochroconis gallopavum infection in a renal transplant re-
cipient: the first reported case and a review of the literature. Clin. Nephrol.
60:415–423. http://dx.doi.org/10.5414/CNP60415.
37. Kralovic SM, Rhodes JC. 1995. Phaeohyphomycosis caused by Dactylaria
(human dactylariosis): report of a case with review of the literature. J.
Infect. 31:107–113. http://dx.doi.org/10.1016/S0163-4453(95)92060-9.
38. Ruping MJ, Albermann N, Ebinger F, Burckhardt I, Beisel C, Muller C,
Vehreschild JJ, Kochanek M, Fatkenheuer G, Bangard C, Ullmann AJ,
Herr W, Kolbe K, Hallek M, Cornely OA. 2008. Posaconazole concen-
trations in the central nervous system. J. Antimicrob. Chemother. 62:
1468–1470. http://dx.doi.org/10.1093/jac/dkn409.
39. Fothergill AW, Rinaldi MG, Sutton DA. 2009. Antifungal susceptibility
testing of Exophiala spp.: a head-to-head comparison of amphotericin B,
itraconazole, posaconazole and voriconazole. Med. Mycol. 47:41–43.
http://dx.doi.org/10.1080/13693780802512451.
40. Al-Abdely HM, Najvar LK, Bocanegra R, Graybill JR. 2005. Antifungal
therapy of experimental cerebral phaeohyphomycosis due to Cladophia-
lophora bantiana. Antimicrob. Agents Chemother. 49:1701–1707. http:
//dx.doi.org/10.1128/AAC.49.5.1701-1707.2005.
41. Calvo E, Pastor FJ, RodriguezMM,Mayayo E, Salas V,Guarro J. 2010.Murine
modelofadisseminatedinfectionbythenovel fungusFonsecaeamonophoraand
successful treatment with posaconazole. Antimicrob. Agents Chemother. 54:
919–923. http://dx.doi.org/10.1128/AAC.01284-09.
42. Graybill JR, Najvar LK, Johnson E, Bocanegra R, Loebenberg D. 2004.
Posaconazole therapy of disseminated phaeohyphomycosis in a murine
model. Antimicrob. Agents Chemother. 48:2288–2291. http://dx.doi.org
/10.1128/AAC.48.6.2288-2291.2004.
43. Marine M, Pastor FJ, Guarro J. 2009. Combined antifungal therapy in a
murine model of disseminated infection by Cladophialophora bantiana.
Med. Mycol. 47:45–49. http://dx.doi.org/10.1080/13693780802526840.
44. Negroni R, Helou SH, Petri N, Robles AM, Arechavala A, Bianchi MH.
2004. Case study: posaconazole treatment of disseminated phaeohypho-
mycosis due to Exophiala spinifera. Clin. Infect. Dis. 38:e15–e20. http:
//dx.doi.org/10.1086/380840.
45. Al-Abdely HM, Alkhunaizi AM, Al-Tawfiq JA, Hassounah M, Rinaldi MG,
SuttonDA. 2005. Successful therapy of cerebral phaeohyphomycosis due to Ra-
michloridiummackenziei with the new triazole posaconazole. Med. Mycol. 43:
91–95. http://dx.doi.org/10.1080/13693780400011104.
46. Seyedmousavi S, Mouton JW, Verweij PE, Bruggemann RJ. 2013.
Therapeutic drug monitoring of voriconazole and posaconazole for inva-
sive aspergillosis. Expert Rev. Anti Infect. Ther. 11:931–941. http://dx.doi
.org/10.1586/14787210.2013.826989.
47. Yarita K, Sano A, Samerpitak K, Kamei K, de Hoog GS, Nishimura K.
2010. Ochroconis calidifluminalis, a sibling of the neurotropic pathogen
O. gallopava, isolated from hot spring. Mycopathologia 170:21–30. http:
//dx.doi.org/10.1007/s11046-010-9292-7.
48. Sides EH, 3rd, Benson JD, Padhye AA. 1991. Phaeohyphomycotic brain
Antifungal Susceptibility of Ochroconis and Verruconis
June 2014 Volume 58 Number 6 aac.asm.org 3291
 o
n
 M
ay 1, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://aac.asm
.org/
D
ow
nloaded from
 
abscess due to Ochroconis gallopavum in a patient with malignant lym-
phoma of a large cell type. J. Med. Vet. Mycol. 29:317–322.
49. Terreni AA, DiSalvo AF, Baker AS, Jr, Crymes WB, Morris PR, Dowda
H, Jr. 1990. Disseminated Dactylaria gallopava infection in a diabetic
patient with chronic lymphocytic leukemia of the T-cell type. Am. J. Clin.
Pathol. 94:104–107.
50. Horré R, de Hoog GS, Kluczny C, Marklein G, Schaal KP. 1999. rDNA
diversity and physiology of Ochroconis and Scolecobasidium species re-
ported from humans and other vertebrates. Stud. Mycol. 43:194–205.
51. DotyMS, Slater DW. 1946. A new species ofHeterobasidium tshawytschae
pathogenic on young chinook salmon. Amer. Midl. Naturalist 36:663–
665.
52. Ge YP, Lv GX, Shen YN, Li M, Deng SW, de Hoog S, Samerpitak K, Liu
WD. 2012. First report of subcutaneous phaeohyphomycosis caused by
Ochroconis tshawytschae in an immunocompetent patient. Med. Mycol.
50:637–640. http://dx.doi.org/10.3109/13693786.2011.653834.
53. Wada S, Nakamura K, Hatai K. 1995. First case of Ochroconis humicola
infection in marine cultured fish in Japan. Fish Pathol. 30:125–126.
54. de Hoog GS, von Arx JA. 1973. Revision of Scolecobasidium and Pleuro-
phragmium. Kavaka 1:55–60.
55. Fassatiová O. 1967. Cˇeská Mykol. 21:87.
56. de Hoog GS. 1985. Taxonomy of the Dactylaria complex, IV. Dactylaria,
Neta, Subulispora and Scolecobasidium. Stud. Mycol. 26:1–60.
57. Zachariah S, Sankaran KV, Leelavathy KM. 1981. A new species of
Septonema from Indian soil. Mycologia 73:208–210.
58. Graniti A. 1962. Scolecobasidium anellii n. sp., agenti di annerimenti su-
perficiali di stalattiti. Giorn. Bot. Ital. 69:360–365.
59. Martin-Sanchez PM, Nováková A, Bastian F, Alabouvette C, Saiz-
Jimenez C. 2012. Two new species of the genus Ochroconis, O. las-
cauxensis and O. anomala isolated from black stains in Lascaux Cave,
France. Fungal Biol. 116:574–589. http://dx.doi.org/10.1016/j.funbio
.2012.02.006.
Seyedmousavi et al.
3292 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 M
ay 1, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://aac.asm
.org/
D
ow
nloaded from
 
